Supplemental Figure S1 KHK2805 KM8188 KM8188/113F(-f)

Slides:

Advertisements

Similar presentations

Supplementary Materials. Supplementary Figure S1. The effect of the freezing/thawing procedure on CD15 and CD33 marker staining on human PBMCs. Prostate.

Advertisements

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Toll-like Receptors in Regulatory T Cells of Patients.

Supplemental Figure 1 A B Supplemental Figure 1. F ‑ IgG and IL-12 mediated NK cell lysis is dependent on the folate receptor availability and does not.

Fluorescence intensity

Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF Xiaoli.

Volume 129, Issue 4, Pages (October 2005)

Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells Mouldy Sioud,

Volume 10, Issue 2, Pages (August 2004)

Supplementary Figure S1

An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma by Stephen D. Gillies, Yan Lan, Steven Williams,

Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805 Munetoshi.

Role of γ/δ T cells in a patient with CD4+ CD3– lymphocytosis, hypereosinophilia, and high levels of IgE Ilan Bank, MDa,d, Avner Reshef, MDb, Miriam.

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases.

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing by Michael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, Roland.

A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities Xiaoqiong Wu, Siqi Chen, Limin Lin, Jiayu Liu, Yanlan Wang, Yumei Li, Qing Li,

Volume 20, Issue 3, Pages (March 2012)

FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity by Ruth A. Ettinger, Joseph A. Liberman,

T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites by Shigeto Yoshida,

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.

WanJun Chen, Mark E Frank, Wenwen Jin, Sharon M Wahl Immunity

Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760) Koji Kurose, MD, Yoshihiro.

Volume 138, Issue 5, Pages e2 (May 2010)

Specific Lysis of Melanoma Cells by Receptor Grafted T Cells is Enhanced by Anti- Idiotypic Monoclonal Antibodies Directed to the scFv Domain of the Receptor

Volume 16, Issue 2, Pages (February 2002)

Volume 25, Issue 12, Pages (December 2017)

Volume 134, Issue 1, Pages (January 2008)

KIR3DL2/CpG ODN Interaction Mediates Sézary Syndrome Malignant T Cell Apoptosis Bouchra Ghazi, Nicolas Thonnart, Martine Bagot, Armand Bensussan, Anne.

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells Mouldy Sioud,

Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15 by Lazar.

Volume 25, Issue 3, Pages (March 2017)

Volume 18, Issue 5, Pages (May 2003)

Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer Tadaaki Yamada, MD, PhD, Shinji Takeuchi,

Integrin α5β1 Activates the NLRP3 Inflammasome by Direct Interaction with a Bacterial Surface Protein Hye-Kyoung Jun, Sung-Hoon Lee, Hae-Ri Lee, Bong-Kyu.

Volume 140, Issue 1, Pages e3 (January 2011)

Marek W.J. Whitehead, Nikolay Khanzhin, Lubor Borsig, Thierry Hennet

Zihua Zeng, Ching-Hsuan Tung, Youli Zu

Molecular Therapy - Nucleic Acids

Volume 7, Issue 4, Pages (October 2016)

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760) Koji Kurose, MD, Yoshihiro.

A Therapeutic Antibody for Cancer, Derived from Single Human B Cells

Volume 26, Issue 4, Pages (April 2018)

Ryang Hwa Lee, Nara Yoon, John C. Reneau, Darwin J. Prockop

Volume 24, Issue 9, Pages (September 2016)

Molecular Therapy - Oncolytics

Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation” Andreas A Hombach, Gunter.

Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.

Volume 42, Issue 2, Pages (February 2015)

The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells Juha Punnonen, MD, PhD, Hans Yssel, PhD,

Volume 16, Issue 1, Pages (January 2002)

Volume 38, Issue 3, Pages (March 2013)

Volume 117, Issue 3, Pages (September 1999)

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect

Volume 20, Issue 5, Pages (May 2012)

Impairment of NK Cell Function by NKG2D Modulation in NOD Mice

Volume 24, Issue 8, Pages (August 2016)

Volume 29, Issue 3, Pages (March 2016)

Volume 17, Issue 5, Pages (May 2009)

Volume 25, Issue 10, Pages (October 2017)

Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma Chien-Kuo.

Volume 21, Issue 4, Pages (April 2013)

Inhibition of miR-449a Promotes Cartilage Regeneration and Prevents Progression of Osteoarthritis in In Vivo Rat Models Dawoon Baek, Kyoung-Mi Lee, Ki.

Flow cytometric analysis of T cell activation.

Anti-CD20 CAR mRNA enhances exPBNK in vitro cytolytic activity against CD20+ B-NHL cells and rituximab-resistant cells. exPBNK were electroporated in the.

Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy Zhenmei Lu, Soosan.

Aptamers for CD Antigens: From Cell Profiling to Activity Modulation

Volume 27, Issue 8, Pages (August 2019)

Volume 12, Issue 5, Pages (November 2005)

Presentation transcript:

Supplemental Figure S1 KHK2805 KM8188 KM8188/113F(-f) Fab region of KHK2805 Fab region of KM8188 113F(-f)-type Fc region IgG1 Fc region N-glycan at Asn297 with fucose N-glycan at Asn297 without fucose Supplemental Figure S1. Construct of KHK2805, KM8188 and KM8188/113F(-f). KHK2805, KM8188 and KM8188/113F(-f) are anti-FOLR1 humanized antibodies. Both KHK2805 and KM8188/113F(-f) have the 113F(-f)-type Fc region [11] for ADCC and CDC enhancement. KM8188 has a human IgG1 type Fc region with fucose on N-glycan at Asn297.

A B Supplemental Figure S2 Supplemental Figure S2. Confirmation of recombinant FOLR2 and FOLR3. Recombinant proteins (0.5 µg/mL FOLR1-Fc, FOLR2-Fc or FOLR3-Fc) were coated onto an ELISA plate. Various concentrations of anti-FOLR2-HRP (LS-C214284, LSBio, A) or anti-FOLR3-HRP (LS-C214296, LSBio, B) were reacted for 1 h, followed by TMB substrate reaction. After stopping the reaction, the A450 nm was measured. Each point represents the mean ± SD of triplicate experiments.

Supplemental Figure S3  + FOLR1-His Supplemental Figure S3. IHC specificity of KM4193. A subcutaneously xenografted SKOV3 tumor was immunohistochemically stained by KM4193 with (+) or without (-) FOLR1-His as a competitor.

Supplemental Figure S4 IGROV1 Control CD46 CD55 CD59 OVMANA SKOV3 OVCAR3 Supplemental Figure S4. The complement regulatory protein expression on OC cells FITC-labeled antibodies for CD46, CD55 and CD59 (BD Biosciences) were used to stain OC cells at 4 C for 30 min. FITC-labeled mouse IgG1 (BD Biosciences) was used as a control antibody. The FITC intensity in the live-cell population was evaluated by FCM.

A B Supplemental Figure S5 Supplemental Figure S5. CDR-optimization caused higher affinity and CDC. (A) The relative affinity of rat/human chimeric KM4193 for FOLR1-His was evaluated by SPR. Humanized (CDR grafted) KM4193 and its CDR-modified versions are described as C101X, wherein C101 means cysteine positioning at 101 in the amino acid sequence of the heavy chain, and X means the substituted amino acid (T, F, I, Q, M, V, G, Y, S, D, A, W, R or P). Humanized KM4193 with C101T is KHK2805. (B) The CDC of anti-FOLR1 antibodies against IGROV1 cells were evaluated as described in the Materials and Methods section. Briefly, human sera were used as the source of complement at a final dilution of 1/6. After 2-h incubation at 37 C, the cell viability was measured. Each point represents the mean ± SD of triplicate experiments.

Supplemental Figure S6 FZ06 FZ44 FZ26 FZ12 FZ21 FZ32 FOLR1-PE Mouse IgG1-PE Not tested Supplemental Figure S6. FOLR1(+) cancer cells in patient-derived ascites samples. The FOLR1(+) cancer cell population was detected in patient-derived ascites samples by FCM as described in the Materials and Methods section. FZ06, FZ44, FZ26, FZ12, FZ21 and FZ32 are the sample IDs. The histograms indicate the intensity of PE-conjugated anti-FOLR1 antibody (FOLR1-PE, A) or the control antibody (Mouse IgG1-PE, B) in the 7-AAD(-)FS(high)CD45(-)CD14(-) cell population. The number in each histogram indicates the percentage of FOLR1(+) cells in the population.

Supplemental Figure S7 IGROV1 cells KHK2805 PBMCs ND Supplemental Figure S7. IP-10 production in the culture supernatant of IGROV1 cell-KHK2805-PBMC coculture. The concentrations of IP-10 in the supernatant after 24-h coculture of IGROV1 cell-KHK2805-PBMC were measured by multi-spot electrochemiluminescence assays using the V-PLEX Human Cytokine 30-Plex Kit supplied by Meso Scale Discovery. +: cultured with IGROV1 cells, 0.01 or 1: cultured with 0.01 or 1 g/mL KHK2805, D1 or D2: cultured with PBMCs from donor 1 or 2 at a PBMC: IGROV1 cell ratio of 25: 1. The lower limit of quantification of IP-10 was 2.412 pg/mL. ND: Not detected.

Supplemental Table S1 Supplemental Table S1. Ex vivo cytotoxic drug resistance profiling of malignant ascites cells. Sample ID FZ06 FZ32 FZ12 FZ26 FZ44 FZ21 Sex F Age 59.9 48.1 50.4 62.4 62.5 75.5 Histology Metastatic serous ovarian carcinoma Ovarian adenocarcinoma Ovarian serous carcinoma Serous ovarian carcinoma Metastatic ovarian carcinoma CYCLOPHOSPHAMIDE R I S CARBOPLATIN CISPLATIN +GEMCITABINE CISPLATIN DOXIL GEMCITABINE TAXOL TOPOTECAN TAXOTERE ETOPOSID The six purchased malignant ascites cell samples and their profiles are listed. “R (Resistance, gray highlighted)” indicates a sample that exhibited no cell death in response to addition of compound, “I (Intermediate)” indicates some cell death, and “S (Sensitive)” indicates that most cells were killed upon treatment. These data were provided by Molecular Response.

Lymphocyte/Cancer cell ratio Supplemental Table S2 Supplemental Table S2. An FCM analysis of the malignant ascites cells. Patient No. FZ06 FZ32 FZ12 FZ26 FZ44 FZ21 FOLR1 expression (MFI) 23106 15129 7615 5169 2594 1451 Lymphocyte/Cancer cell ratio 0.12 0.13 0.10 0.53 0.57 1.85 NK (% Lymphocyte) 7.4 10.6 10.3 10.4 15.8 19.8 T (% Lymphocyte) 33.9 46.3 25.5 34.4 67.3 38.5 The FOLR1 expression (mean fluorescent intensity, MFI) of cancer cells and the number of NK and T cells in the malignant ascites cells were evaluated by FCM as described in the Materials and Methods section. The numbers of NK and T cells are described as percentages relative to lymphocytes in the ascites.